A citation-based method for searching scientific literature

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli, Jessica Read, Peter Langmuir, Anderson J Ryan, Martin J Schlumberger. J Clin Oncol 2012
Times Cited: 839



Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
M Schlumberger, R Elisei, S Müller, P Schöffski, M Brose, M Shah, L Licitra, J Krajewska, M C Kreissl, B Niederle, E E W Cohen, L Wirth, H Ali, D O Clary, Y Yaron, M Mangeshkar, D Ball, B Nelkin, S Sherman. Ann Oncol 2017
Times Cited: 76




List of shared articles



Times cited

State of the art and future directions in the systemic treatment of medullary thyroid cancer.
Eline C Jager, K Esther Broekman, Schelto Kruijff, Thera P Links. Curr Opin Oncol 2022
1

In silico Analysis of Publicly Available Transcriptomics Data Identifies Putative Prognostic and Therapeutic Molecular Targets for Papillary Thyroid Carcinoma.
Asma Almansoori, Poorna Manasa Bhamidimarri, Riyad Bendardaf, Rifat Hamoudi. Int J Gen Med 2022
0

Medullary thyroid cancer - An update.
Laura Fugazzola. Best Pract Res Clin Endocrinol Metab 2022
0

Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer.
Evan Walgama, Naifa Busaidy, Mark Zafereo. Endocrinol Metab Clin North Am 2022
0

Targeted therapy and drug resistance in thyroid cancer.
Yujie Zhang, Zhichao Xing, Tianyou Liu, Minghai Tang, Li Mi, Jingqiang Zhu, Wenshuang Wu, Tao Wei. Eur J Med Chem 2022
0

Multiple endocrine neoplasia type 2: A review.
Jes Sloth Mathiesen, Grigoris Effraimidis, Maria Rossing, Åse Krogh Rasmussen, Lise Hoejberg, Lars Bastholt, Christian Godballe, Peter Oturai, Ulla Feldt-Rasmussen. Semin Cancer Biol 2022
5

A contemporary review of rearranged during transfection-selective inhibitors.
Angel W Liu, Connie Liang, Chung-Shien Lee. J Oncol Pharm Pract 2022
1

Real-world insights into the efficacy and safety of tyrosine kinase inhibitors against thyroid cancers.
Lingyu Li, Lin Cheng, Ri Sa, Xian Qiu, Libo Chen. Crit Rev Oncol Hematol 2022
1

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Antonio Matrone, Carla Gambale, Alessandro Prete, Rossella Elisei. Front Endocrinol (Lausanne) 2022
1

ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.
S Filetti, C Durante, D M Hartl, S Leboulleux, L D Locati, K Newbold, M G Papotti, A Berruti. Ann Oncol 2022
0

The Role of the Kinase Inhibitors in Thyroid Cancers.
Francesca Cuomo, Claudio Giani, Gilda Cobellis. Pharmaceutics 2022
0

New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
Matthew D Ringel. J Clin Endocrinol Metab 2021
5

Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
Ashleigh Porter, Deborah J Wong. Front Oncol 2021
13

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.
Carrie C Lubitz, Peter M Sadow, Gilbert H Daniels, Lori J Wirth. Thyroid 2021
5

Cardiovascular Toxicities Secondary to Biotherapy and Molecular Targeted Therapies in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Charalampos Aktypis, Maria-Eleni Spei, Maria Yavropoulou, Göran Wallin, Anna Koumarianou, Gregory Kaltsas, Eva Kassi, Kosmas Daskalakis. Cancers (Basel) 2021
2

Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
Zoe A Efstathiadou, Charalambos Tsentidis, Alexandra Bargiota, Vasiliki Daraki, Kalliopi Kotsa, Georgia Ntali, Labrini Papanastasiou, Stelios Tigas, Konstantinos Toulis, Kalliopi Pazaitou-Panayiotou,[...]. Eur Thyroid J 2021
4

Current Guidelines for Management of Medullary Thyroid Carcinoma.
Mijin Kim, Bo Hyun Kim. Endocrinol Metab (Seoul) 2021
2

Precision therapy for RET-altered cancers with RET inhibitors.
Kyaw Z Thein, Vamsidhar Velcheti, Blaine H M Mooers, Jie Wu, Vivek Subbiah. Trends Cancer 2021
8

Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.
Kinga Hińcza-Nowak, Artur Kowalik, Agnieszka Walczyk, Iwona Pałyga, Danuta Gąsior-Perczak, Agnieszka Płusa, Janusz Kopczyński, Magdalena Chrapek, Stanisław Góźdź, Aldona Kowalska. Genes (Basel) 2021
0

Effects of marital status on survival of medullary thyroid cancer stratified by age.
Lei Ai, Ning Li, Hai-Long Tan, Bo Wei, Ya-Xin Zhao, Pei Chen, Hui-Yu Hu, Mian Liu, Deng-Jie Ou-Yang, Zi-En Qin,[...]. Cancer Med 2021
1

Management of VEGFR-Targeted TKI for Thyroid Cancer.
Tomohiro Enokida, Makoto Tahara. Cancers (Basel) 2021
0


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy